ORYZON GENOMICS, S.A. «12345...» Página 2 de 11 desde 01/07/1988 hasta 30/04/2024 16/07/2019 09:05 ORYZON GENOMICS, S.A. R&D: new licenses, patents and registered trademarks ORYZON announces that data from its ETHERAL Phase IIa clinical trial of vafidemstat in Alzheimer’s patients were presented yesterday at the Alzheimer´s Association International Conference (AAIC-2019) Número de registro: 280225 14/06/2019 07:35 ORYZON GENOMICS, S.A. R&D: new licenses, patents and registered trademarks Oryzon presents iadademstat preliminary efficacy data from the ALICE Phase IIa trial in acute myeloid leukemia Número de registro: 279154 17/05/2019 13:32 ORYZON GENOMICS, S.A. Announcements and resolutions of general shareholders meetings Oryzon Genomics, S.A. informs about the resolutions passed by the Ordinary General Shareholders’ Meeting. Número de registro: 278353 Relacionado con 276934 del 09/04/2019 (07:45) 13/05/2019 14:49 ORYZON GENOMICS, S.A. Interim financial information La sociedad remite información sobre los resultados del primer trimestre de 2019 Número de registro: 278170 25/04/2019 06:28 ORYZON GENOMICS, S.A. R&D: new licenses, patents and registered trademarks Oryzon presents vafidemstat efficacy data from the REIMAGINE Phase IIa trial’s Attention Deficit Hyperactivity Disorder (ADHD) cohort Número de registro: 277371 09/04/2019 07:45 ORYZON GENOMICS, S.A. Announcements and resolutions of general shareholders meetings Call of the Ordinary General Shareholders’ Meeting of Oryzon Genomics, S.A. Número de registro: 276934 Relacionado con 278353 del 17/05/2019 (13:32) 08/04/2019 07:06 ORYZON GENOMICS, S.A. R&D: new licenses, patents and registered trademarks Oryzon presents vafidemstat efficacy data from the REIMAGINE Phase II trial’s Borderline Personality Disorder cohort at the 27th European Congress of Psychiatry (EPA 2019) Número de registro: 276888 20/03/2019 08:07 ORYZON GENOMICS, S.A. R&D: new licenses, patents and registered trademarks Oryzon to present topline preliminary results on Vafidemstat’s Reimagine Phase IIa trial on the cohort of Borderline Personality Disorder Número de registro: 276239 11/03/2019 07:12 ORYZON GENOMICS, S.A. R&D: new licenses, patents and registered trademarks Approval by the U.S. Food and Drug Administration (FDA) of its Investigational New Drug application (IND) for ETHERAL, a PhIIa clinical trial of vafidemstat (ORY-2001) Número de registro: 275854 15/02/2019 16:57 ORYZON GENOMICS, S.A. Board of directors remuneration annual statement La Sociedad remite el Informe Anual sobre remuneraciones de los consejeros del Ejercicio 2018 Número de registro: 274764 Página 2 de 11 «12345...»